Funds › RA Capital Management, L.P.
RA Capital Management, L.P.
13F for Q2 2026, filed Aug 14, 2026. 84 positions worth $11.5B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$11.5B
+$2.1B (21.9%) vs Q1 2026
Positions
84
85 in Q1 2026
Top 10 share
60.4%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of RA Capital Management, L.P. in the latest 13F quarter?
Using 13F.ai, how has RA Capital Management, L.P.'s portfolio concentration changed over the last four quarters?
Using 13F.ai, which of RA Capital Management, L.P.'s top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | ASND Ascendis Pharma A/S | 10.28M | $2.7B | 23.8% | New | 13F ↗ |
| 2 | PBLS Parabilis Medicines, Inc. | 28.93M | $791.9M | 6.9% | New | 13F ↗ |
| 3 | RYTM Rhythm Pharmaceuticals, Inc. | 6.67M | $740.2M | 6.4% | Unchanged | 13F ↗ |
| 4 | PCVX Vaxcyte, Inc. | 11.47M | $667.0M | 5.8% | Unchanged | 13F ↗ |
| 5 | SION Sionna Therapeutics, Inc. | 9.91M | $435.7M | 3.8% | Unchanged | 13F ↗ |
| 6 | TYRA Tyra Biosciences, Inc. | 12.20M | $389.6M | 3.4% | Unchanged | 13F ↗ |
| 7 | EWTX Edgewise Therapeutics, Inc. | 8.39M | $341.0M | 3.0% | -19.5% | 13F ↗ |
| 8 | NAMS NewAmsterdam Pharma Company N.V. | 9.55M | $323.7M | 2.8% | Unchanged | 13F ↗ |
| 9 | COAG Hemab Therapeutics Holdings, Inc. | 7.81M | $286.8M | 2.5% | New | 13F ↗ |
| 10 | SEPN Septerna, Inc. | 7.00M | $234.3M | 2.0% | Unchanged | 13F ↗ |
| 11 | BCAX Bicara Therapeutics Inc. | 7.26M | $215.4M | 1.9% | Unchanged | 13F ↗ |
| 12 | MLYS Mineralys Therapeutics, Inc. | 7.69M | $207.6M | 1.8% | Unchanged | 13F ↗ |
| 13 | GHRS GH Research PLC | 7.64M | $205.3M | 1.8% | -0.5% | 13F ↗ |
| 14 | IRON Disc Medicine, Inc. | 2.45M | $179.2M | 1.6% | Unchanged | 13F ↗ |
| 15 | SGP SpyGlass Pharma, Inc. | 8.02M | $178.6M | 1.6% | Unchanged | 13F ↗ |
| 16 | ARTV Artiva Biotherapeutics, Inc. | 17.96M | $174.2M | 1.5% | +82.2% | 13F ↗ |
| 17 | JANX Janux Therapeutics, Inc. | 11.19M | $171.9M | 1.5% | Unchanged | 13F ↗ |
| 18 | TSHA Taysha Gene Therapies, Inc. | 23.56M | $160.4M | 1.4% | Unchanged | 13F ↗ |
| 19 | BCRX BioCryst Pharmaceuticals, Inc. | 15.83M | $158.3M | 1.4% | Unchanged | 13F ↗ |
| 20 | Wave Life Sciences Ltd | 26.98M | $156.7M | 1.4% | Unchanged | 13F ↗ |
| 21 | Nuvalent Inc | 1.25M | $153.9M | 1.3% | -50.8% | 13F ↗ |
| 22 | ABVX Abivax SA · ADR | 1.13M | $150.9M | 1.3% | New | 13F ↗ |
| 23 | ORKA Oruka Therapeutics, Inc. | 1.55M | $148.0M | 1.3% | New | 13F ↗ |
| 24 | CLYM Climb Bio, Inc. | 11.30M | $147.4M | 1.3% | Unchanged | 13F ↗ |
| 25 | SLDB Solid Biosciences Inc. | 12.04M | $120.2M | 1.0% | +28.9% | 13F ↗ |
| 26 | ZLAB Zai Lab Limited · ADR | 5.74M | $109.1M | 0.9% | +0.6% | 13F ↗ |
| 27 | SPRY ARS Pharmaceuticals, Inc. | 10.86M | $87.0M | 0.8% | Unchanged | 13F ↗ |
| 28 | XNCR Xencor, Inc. | 5.27M | $84.9M | 0.7% | +7.7% | 13F ↗ |
| 29 | JBIO Jade Biosciences, Inc. | 3.67M | $81.6M | 0.7% | Unchanged | 13F ↗ |
| 30 | NTLA Intellia Therapeutics, Inc. | 4.53M | $76.6M | 0.7% | New | 13F ↗ |
| 31 | LBRX LB Pharmaceuticals Inc | 2.21M | $71.7M | 0.6% | Unchanged | 13F ↗ |
| 32 | DFTX Definium Therapeutics, Inc. | 1.50M | $70.6M | 0.6% | New | 13F ↗ |
| 33 | ACRS Aclaris Therapeutics, Inc. | 12.72M | $67.3M | 0.6% | +87.0% | 13F ↗ |
| 34 | FDMT 4D Molecular Therapeutics, Inc. | 5.05M | $67.2M | 0.6% | Unchanged | 13F ↗ |
| 35 | SANA Sana Biotechnology, Inc. | 18.75M | $65.4M | 0.6% | New | 13F ↗ |
| 36 | Damora Therapeutics Inc | 2.40M | $62.4M | 0.5% | Unchanged | 13F ↗ |
| 37 | MNPR Monopar Therapeutics Inc. | 667,207 | $61.8M | 0.5% | Unchanged | 13F ↗ |
| 38 | ABOS Acumen Pharmaceuticals, Inc. | 20.99M | $56.1M | 0.5% | Unchanged | 13F ↗ |
| 39 | GERN Geron Corporation | 42.81M | $54.8M | 0.5% | -32.9% | 13F ↗ |
| 40 | RZLT Rezolute, Inc. | 9.45M | $49.1M | 0.4% | +2.9% | 13F ↗ |
| 41 | EVMN Evommune, Inc. | 3.49M | $46.4M | 0.4% | Unchanged | 13F ↗ |
| 42 | VOR Vor Biopharma Inc. | 2.40M | $44.2M | 0.4% | -55.6% | 13F ↗ |
| 43 | IPSC Century Therapeutics, Inc. | 17.75M | $43.5M | 0.4% | Unchanged | 13F ↗ |
| 44 | AKTS Aktis Oncology, Inc. | 1.31M | $42.4M | 0.4% | -12.6% | 13F ↗ |
| 45 | BIOA BioAge Labs, Inc. | 1.67M | $41.0M | 0.4% | +1.3% | 13F ↗ |
| 46 | CCCC C4 Therapeutics, Inc. | 8.00M | $37.4M | 0.3% | Unchanged | 13F ↗ |
| 47 | MIRM Mirum Pharmaceuticals, Inc. | 318,554 | $37.3M | 0.3% | Unchanged | 13F ↗ |
| 48 | CAPR Capricor Therapeutics, Inc. | 1.51M | $36.3M | 0.3% | Unchanged | 13F ↗ |
| 49 | PEPG PepGen Inc. | 20.06M | $36.1M | 0.3% | Unchanged | 13F ↗ |
| 50 | PRLD Prelude Therapeutics Incorporated | 6.48M | $34.5M | 0.3% | New | 13F ↗ |
Showing the top 50 of 84 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
17 new, 10 added to, 10 trimmed, 18 exited, 47 unchanged. By estimated dollars.
New positions (17)
| ASND Ascendis Pharma A/S | 10.28M | New | $2.7B |
| PBLS Parabilis Medicines, Inc. | 28.93M | New | $791.9M |
| COAG Hemab Therapeutics Holdings, Inc. | 7.81M | New | $286.8M |
| ABVX Abivax SA · ADR | 1.13M | New | $150.9M |
| ORKA Oruka Therapeutics, Inc. | 1.55M | New | $148.0M |
| NTLA Intellia Therapeutics, Inc. | 4.53M | New | $76.6M |
| DFTX Definium Therapeutics, Inc. | 1.50M | New | $70.6M |
| SANA Sana Biotechnology, Inc. | 18.75M | New | $65.4M |
| PRLD Prelude Therapeutics Incorporated | 6.48M | New | $34.5M |
| QTTB Q32 Bio Inc. | 2.33M | New | $29.7M |
Added to (10)
| ARTV Artiva Biotherapeutics, Inc. | 17.96M | +82.2% | $78.6M |
| ACRS Aclaris Therapeutics, Inc. | 12.72M | +87.0% | $31.3M |
| SLDB Solid Biosciences Inc. | 12.04M | +28.9% | $26.9M |
| ACRV Acrivon Therapeutics, Inc. | 12.23M | +46.6% | $6.9M |
| AVTX Avalo Therapeutics, Inc. | 1.00M | +50.8% | $6.2M |
| XNCR Xencor, Inc. | 5.27M | +7.7% | $6.1M |
| RZLT Rezolute, Inc. | 9.45M | +2.9% | $1.4M |
| ZLAB Zai Lab Limited · ADR | 5.74M | +0.6% | $689.1K |
| BIOA BioAge Labs, Inc. | 1.67M | +1.3% | $514.7K |
| Damora Therapeutics Inc | 2.40M | Unchanged | $10.2K |
Trimmed (10)
| Nuvalent Inc | 1.25M | -50.8% | -$159.0M |
| EWTX Edgewise Therapeutics, Inc. | 8.39M | -19.5% | -$82.7M |
| VOR Vor Biopharma Inc. | 2.40M | -55.6% | -$55.3M |
| GERN Geron Corporation | 42.81M | -32.9% | -$26.8M |
| AKTS Aktis Oncology, Inc. | 1.31M | -12.6% | -$6.1M |
| ACET Adicet Bio, Inc. | 932,624 | -21.1% | -$2.2M |
| HOWL Werewolf Therapeutics, Inc. | 2.39M | -64.3% | -$1.5M |
| GHRS GH Research PLC | 7.64M | -0.5% | -$1.1M |
| OVID Ovid Therapeutics Inc. | 10.50M | -2.0% | -$573.1K |
| PTN Palatin Technologies, Inc. | 62,124 | -11.3% | -$85.0K |
Exited (18)
| Ascendis Pharma A/S ADR | 10.28M | Exited | -$2.4B |
| DNTH Dianthus Therapeutics, Inc. | 2.61M | Exited | -$219.2M |
| PRAX Praxis Precision Medicines, Inc. | 373,787 | Exited | -$120.4M |
| SRPT Sarepta Therapeutics, Inc. | 3.90M | Exited | -$84.9M |
| SYRE Spyre Therapeutics, Inc. | 1.62M | Exited | -$81.8M |
| FULC Fulcrum Therapeutics, Inc. | 6.05M | Exited | -$46.4M |
| OLMA Olema Oncology, Inc. | 2.60M | Exited | -$38.8M |
| DSGN Design Therapeutics, Inc. | 2.97M | Exited | -$31.6M |
| TVTX Travere Therapeutics, Inc. | 746,841 | Exited | -$22.2M |
| GRAL GRAIL, Inc. | 428,266 | Exited | -$22.1M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer